medigraphic.com
ISSN 0016-3813 (Impreso)

2004, Número 5

<< Anterior Siguiente >>

Gac Med Mex 2004; 140 (5)


Trasplante autólogo de médula ósea como tratamiento de enfermedades autoinmunes: mecanismos y resultados

Garza-Madrid ME, Borbolla-Escoboza JR, López-Hernández MA

Idioma: Español
Referencias bibliográficas: 66
Paginas: 531-539
Archivo PDF: 77.65 Kb.


RESUMEN

Las enfermedades autoinmunes se caracterizan por una respuesta del sistema inmune del individuo hacia tejidos propios. Una línea de investigación actual es el tratamiento de estas enfermedades y el desarrollo de tolerancia. Una de las opciones en la búsqueda del desarrollo de tolerancia es el trasplante autólogo de médula ósea: la variantes del trasplante de médula ósea que hace uso de células progenitoras hematopoyéticas propias. La posibilidad de usar este tipo de trasplante como tratamiento de enfermedades autoinmunes se originó en los hallazgos de remisiones de enfermedades autoinmunes coexistentes, en pacientes que eran trasplantados por enfermedades oncológicas. En esta revisión presentemos el fundamento teórico de este tratamiento, así como una recopilación de los estudios preclínicos y clínicos más relevantes en esta materia. Aunque algún reporte inicial puso en duda la utilidad de dicho procedimiento, en general, los resultados son alentadores. Es necesario que más pacientes en diversos estadios de las enfermedades autoinmunes sean referidos a centros especializados de manera que sea posible recopilar la información de manera ordenada y sistemática, y se pueda arribar a un conocimiento sobre el papel que juega este tipo de tratamiento en las enfermedades autoinmunes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rotrosen D, Matthews JB, Bluestone JA. The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol 2002;110:17-23.

  2. Huston DP. The biology of the immune system. JAMA 1997;278:1804-1814. 3. Chaplin DD. The immune system: overview of the immune response. J Allergy Clin Immunol 2003;111:5442-5459.

  3. Burt RK, Slavin S, Burns WS, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem celí transplantation: getting closer to a cure. Blood 2002;99:768-784.

  4. Martin TG, Linker CA. Autologous stem ceIl transplantation for acute Iymphocytic leukemia in adults. Hematol Oncol Clin North Am 2001;15:121-143.

  5. Hoffman R, Benz Jr EJ, Shattil SJ, et al. editores. Hematology: basic principies and practice. Phildelphia: Churchill Livingstone; 2000. p. 2326-2334.

  6. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-838.

  7. Horak DA, Forman SJ. Critical care of the hematopoietic stem cell patient. Crit Care Clin 2001;17:671-695.

  8. Kozák T, Rychlík I. Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases. IMAJ 2002;4:268-271.

  9. Marmont AM. Historical perspectives, rationale and future directions for hematopoietic stem cell transplantation for severe autoimmune diseases. Haematologica 2002;87(Suppl 8):24-27.

  10. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in autoimmune disease A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood Marrow Transpiantation (EBMT). Br J Rheumatol 1997;36:390-392.

  11. Vogel A, Manns MP, Strassburg CP. Autoimmunity and viruses. Clin Liver Dis 2002;6:451-465.

  12. Euler HH, Marmont AM, Bacigalupo A, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem ceIl transplantation. Blood 1996;88:3621-3625.

  13. Tyndall A, Gratwohl A. Immune ablation and stem cell therapy in autoimmune disease Clinical experience. Arthritis Res 2000;2:276-280.

  14. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple Sclerosis. N Engl J Med 2000;343:938-952.

  15. Medical Advisory Board of the National Multiple Sclerosis Society. Disease management consensus statement. New York: National Múltiple Sclerosis Society;2002.

  16. Halfpenny C, Benn T, Scolding N. Cell transplantation, myelin repair, and multiple sclerosis. Lancet Neurol 2002;1:31-40.

  17. Fassas A, Anagnostopobus A, Kazis A, et al. Autologous stem cell transplantation in progresive múltiple sclerosis - an interim analysis of efficacy. J Clin Immunol 2000;20:24-30.

  18. Carreras E, Saiz A, Marín P, et al. CD34+ selected autologous peripheral blood stem cell transpíantation for multiple sclerosis: report of toxicitv and treatment results at one year of follow-up in 15 patients. Haematologica 2003;88:306-314.

  19. Burt RK, Cohen BA, Rusel E, Spero K, Joshi A, Oyama Y, et al. Hematopoietic stem celí transpíantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003;102:2373-2378.

  20. Nash RA, Bowen JD, McSweeney PA, Sullivan KM, Pavletic S, Maravilla KR, et al. Treatment of severe multiple sclerosis (MS) with high-dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT): 2 year follow-up. Blood 2002;100(Supl.1):3408.

  21. Kozak T, Havdrova E, Pitha J, Gregora E, Pytlik R, Maaloufova J, et al. High dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000;25:525-531.

  22. Openshaw H, Lund BT, Kashyap A, Atkinson R, Sniecinski I, Weiner L, Forman S. Peripheral blood stem celí transpíantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000;(6):563-575.

  23. Mancardi GL, Saccardi R, Filippi M, et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001;57:62-68.

  24. Saccardi R, Mancardi G, Bacigalupo A, Di Bartolomeo P, Donelli A, Gualdandi F, et al. Autologous hematopoietic stem cell transplantation in secondary progressive MS: Clinical, instrumental findings and impact on quality of life. Blood 2002;100(supl.1):3409.

  25. Novik M, lonova T, Bisaga G, Melnickenko V. Chelombit L, Kishtovich A. Quality of life and EDSS dynamics in multiple sclerosis patients undergoing high dose chemotherapy and autologous stem cell transplantation. Blood 2002;100(suppl 1):5481.

  26. Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP, et al. Multiple sclerosis flares associated with recombinant granulocyte colonystimulating factor. Neurology 2000;54:2147-2150.

  27. Gaffney PM, Moser KL, Graham RR, Behrens TW. Recent advances in the genetics of systemic lupus erythematosus. Rheum Dis Clin North Am 2002;28:111-126.

  28. Brasington Jr RD, Kahl LE, Ranganathan P, Latinis KM, Velazquez C, Atkinson JP. Immunologic rheumatic disorders. J Allergy Clin Immunol 2003;111:S593-601.

  29. Petri M. Treatment of systemic lupus erythematosus: an update. Am Fam Physician 1998;57:2753-2760.

  30. Trysberg E, Lindgren I, Tarkowski A. Autologous stem cell transplantation in a case of treatment resistant central nervous system lupus. Ann Rheum Dis 2000;59:236-238.

  31. Fouillard L, Gorin NC, Laporte JP, Leon A, Brantus JF, Miossec P. Control of severe systemic lupus erythematosus after high-dose immunosuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood. Lupus 1999;8:320-323.

  32. Musso M, Porretto F, Crescimanno A, Bondi F, Polizzi V, Scalone R, et al. Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome. Lupus 1998;7:492-494.

  33. Marmont AM, van Lint MT, Gualandi F, Bacigalupo A. Autologous marrow stem cell transplantation for severe systemic lupus erithematosus of long duration. Lupus 1997;6:545-548.

  34. Shaughnessy PJ, Ririe DW, Ornstein DL, Kissack B, Bickford DJ, Molir R, et al. Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue. Bone Marrow Transplant 2001;27:221-224.

  35. Brunner M, Greinix HT, Redlich K, Knobl P, Smolen J, Leitner G, et al. Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report. Arthritis Rheum 2002;46:1580-1584.

  36. Ouyang J, Sun L, Yang Y, Chen B1 Han X, Fan X. A pilot study in treatment of systemic lupus ervthematosus by autologus bone marrow transplant (Abstract). Shonghua Nei Ke Za Zhi 2001;40:229-231.

  37. Traynor AE, Barr WG, Rosa RM, Rodriguez J, Oyama Y, Baker S, et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002;46:2917- 2923.

  38. Burt RK, Traynor AE, Pope R, Schoeder J, Cohen B, Karlin KH, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998;10:3505-3514.

  39. Zintl F, Schiller I, Mueller A, Aumann V, Kentouche K, Fuchs D, et al. Treatment of children and adolescents with juvenile rheumatoid arthritis (JRA) and severe systemic lupus erythematosus (SLE) with high dose chemotherapy and autologous stem cell transplantation (Abstract). Blood 2002;100 (supl.1):5479.

  40. Boers M. Rheumatoid arthritis. Treatment of early disease. Rheum Dis Clin North Am 2001;2:405-414.

  41. O’Dell JR. Combinations of conventional disease modifying antirheumatic drugs. Rheum Dis Clin North Am 2001;2:415-426.

  42. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleishmann RM, Fox Rl, et al. A trial of Etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving Methotrexate. NEJM 1999;340:253-259.

  43. Burt RK, Georganas C, Schroeder J, Traynor A, Stefka J, Schuening F, et al. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis. Arthritis Rheum 1999;42:2281-2285.

  44. Snowden JA, Biggs JC, Milliken ST, Fuller A, Brooks PM. A phase I/II dose escalation study of intensified cvclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum 1999;42:2286-2292.

  45. Verburg RJ, Kruize M, van den Hoogen FH, Fibbe WE, Petersen EJ, Preijers F, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum 2001;44:754-60.

  46. Espigado Tocino I, García López A, Valenzuela Castaño A, Rodríguez Fernández JM. Autotrasplante de progenitores hematopoyéticos en una paciente con artritis reumatoide. Med Clin 2001;117:399-399.

  47. Leng X, Zhao Y, Zhou D, Li T, Tang F, Zeng X, et al. Study of treatment of refractory rheumatoid arthritis with autologous peripheral blood stem cell transplantation (Abstract). Zhonghua Yi Xue Za Zhi 2002;82(11):748-51.

  48. Kim KC, Lee IH, Choi JH, Oh MR, Ahn MJ, Kim SY. Autologous stem cell transplantation in the treatment of refracton’ rheumatoid arthritis. J Korean Med Sci 2002;17:129-132.

  49. Pavletic SZ, Odell JR, Pirrucello SJ, Ursick MM, Haire CE, Sharp JG, et al. Intensive immunoablation and autologous blood stem cell transplantation in patients with refractory rheumatoid arthritis the University of Nebraska experience. J Rheumatol Suppl 2001;64:13-20.

  50. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002;46:2301-2309.

  51. Van Laar JM, Verburg RJ, Fibbe WE, Breedveld FC. Intensive immunosuppression and autologous stem cell transplantation for patients with severe rheumatoid arthritis: the Leiden experience. J Rheumatol Suppl 2001;64;25-27 (Abstract).

  52. Bingham SJ, Snowden J, McGonagle D, Richards S, Isaacs J, Morgan G, et al. Autologous stem cell transplantation for rheumatoid arthritis - interim report of 6 patients. J Rheumatol Suppl 2001;64:21-24.

  53. Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatries 2002;109:109-115.

  54. Hashkes PJ, Friedland O, Uziel Y. New treatments for juvenile idiopathic arthritis. IMAJ 2002;4:39-43.

  55. Tessel EM, van der Net J, Cuis W, Wulfraat NM. Outcome status in chudren with sustained polyarticular and systemic juvenile idiopathic arthritis. Rheumatology 2001;40:225-226.

  56. Brinkman DM, ten Cate R, Vossen JM, Smeets TJ, Kraan MC, Tak PP. Decrease in synovial cellularity and cvtokine expression after autologous stem cell transplantation in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:1121-1123.

  57. Nakagawa R, Kawano Y, Yoshimura E, Suzuya H, Watanabe T, Kanamaru S, et al. Intense immunosuppression followed by purified blood CD34+ cell autografting in a patient with refractory juvenile rheumatoid arthritis. Bone Marrow Transplant 2001;27:333-336.

  58. Wulffraat M, de Kleer I, Brinkman D, ten Cate R, van der Net JJ, RUkers GT, et al. Autologous stem cell transpíantation for refractory juvenile idiopathic arthritis: current results and perspectives. Transplantation Proceedings 2002;34:2925-2926.

  59. Wedderburn LR, Patel A, King D, Varsani H, Foster HE, Abinun MM. Long term follow up of immune repertory after severe immunosuppression and autologous stem cell rescue in children with juvenile idiopathic arthritis. American College of Rheumathology 2003 annual meeting. Abstract 142

  60. Lin ATH, Clements PJ, Furst DE. Update on disease modifving antirheumatic drugs in the treatment of systemic sclerosis. Rheum Dis Clin N Am 2003;29:409-426.

  61. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychological welI being. Rheum Dis Clin N Am 2003;29:255-273.

  62. Furst DE, Tyndall A. Stem cell transplantation in systemic sclerosis: rationale and status report. IMA) 2000;2:935-937.

  63. Mcsweeney PA, Nash PA, Sullivan KM, Storek J, Crofford U, Dansey R, et al. High-dose imminosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100:1602-1610.

  64. Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: erly results from a French multicentre phase I-II study. Br J Haematol 2002;119:726-739.

  65. Lo Monaco A, Lanza F, Dabusti M, Padovan M, La Corte R, Castoldi G, et al. Autologous stem cell transplantation in a patient with diffuse systemic sclerosis. Reumatismo 2002;54:351-356.

  66. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001;60:548-549.




2020     |     www.medigraphic.com